Cargando…
In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers
A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12–17 and urea heterodimers 18–22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspec...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450562/ https://www.ncbi.nlm.nih.gov/pubmed/30938202 http://dx.doi.org/10.1080/14756366.2019.1593159 |
_version_ | 1783409041216634880 |
---|---|
author | Janockova, Jana Korabecny, Jan Plsikova, Jana Babkova, Katerina Konkolova, Eva Kucerova, Dana Vargova, Jana Koval, Jan Jendzelovsky, Rastislav Fedorocko, Peter Kasparkova, Jana Brabec, Viktor Rosocha, Jan Soukup, Ondrej Hamulakova, Slavka Kuca, Kamil Kozurkova, Maria |
author_facet | Janockova, Jana Korabecny, Jan Plsikova, Jana Babkova, Katerina Konkolova, Eva Kucerova, Dana Vargova, Jana Koval, Jan Jendzelovsky, Rastislav Fedorocko, Peter Kasparkova, Jana Brabec, Viktor Rosocha, Jan Soukup, Ondrej Hamulakova, Slavka Kuca, Kamil Kozurkova, Maria |
author_sort | Janockova, Jana |
collection | PubMed |
description | A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12–17 and urea heterodimers 18–22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspected in vitro on the HL-60 cell line using different flow cytometric techniques (cell cycle distribution, detection of mitochondrial membrane potential dissipation, and analysis of metabolic activity/viability). The compounds exhibited a profound inhibitory effect on topoisomerase activity (e.g. compound 22 inhibited type I topoisomerase at 1 µM concentration). The treatment of HL-60 cells with the studied compounds showed inhibition of cell growth especially with hybrids containing thiourea (14–17) and urea moieties (21 and 22). Moreover, treatment of human dermal fibroblasts with the studied compounds did not indicate significant cytotoxicity. The observed results suggest beneficial selectivity of the heterodimers as potential drugs to target cancer cells. |
format | Online Article Text |
id | pubmed-6450562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64505622019-04-15 In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers Janockova, Jana Korabecny, Jan Plsikova, Jana Babkova, Katerina Konkolova, Eva Kucerova, Dana Vargova, Jana Koval, Jan Jendzelovsky, Rastislav Fedorocko, Peter Kasparkova, Jana Brabec, Viktor Rosocha, Jan Soukup, Ondrej Hamulakova, Slavka Kuca, Kamil Kozurkova, Maria J Enzyme Inhib Med Chem Research Article A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12–17 and urea heterodimers 18–22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspected in vitro on the HL-60 cell line using different flow cytometric techniques (cell cycle distribution, detection of mitochondrial membrane potential dissipation, and analysis of metabolic activity/viability). The compounds exhibited a profound inhibitory effect on topoisomerase activity (e.g. compound 22 inhibited type I topoisomerase at 1 µM concentration). The treatment of HL-60 cells with the studied compounds showed inhibition of cell growth especially with hybrids containing thiourea (14–17) and urea moieties (21 and 22). Moreover, treatment of human dermal fibroblasts with the studied compounds did not indicate significant cytotoxicity. The observed results suggest beneficial selectivity of the heterodimers as potential drugs to target cancer cells. Taylor & Francis 2019-04-02 /pmc/articles/PMC6450562/ /pubmed/30938202 http://dx.doi.org/10.1080/14756366.2019.1593159 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Janockova, Jana Korabecny, Jan Plsikova, Jana Babkova, Katerina Konkolova, Eva Kucerova, Dana Vargova, Jana Koval, Jan Jendzelovsky, Rastislav Fedorocko, Peter Kasparkova, Jana Brabec, Viktor Rosocha, Jan Soukup, Ondrej Hamulakova, Slavka Kuca, Kamil Kozurkova, Maria In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title | In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title_full | In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title_fullStr | In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title_full_unstemmed | In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title_short | In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers |
title_sort | in vitro investigating of anticancer activity of new 7-meota-tacrine heterodimers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450562/ https://www.ncbi.nlm.nih.gov/pubmed/30938202 http://dx.doi.org/10.1080/14756366.2019.1593159 |
work_keys_str_mv | AT janockovajana invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT korabecnyjan invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT plsikovajana invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT babkovakaterina invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT konkolovaeva invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT kucerovadana invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT vargovajana invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT kovaljan invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT jendzelovskyrastislav invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT fedorockopeter invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT kasparkovajana invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT brabecviktor invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT rosochajan invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT soukupondrej invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT hamulakovaslavka invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT kucakamil invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers AT kozurkovamaria invitroinvestigatingofanticanceractivityofnew7meotatacrineheterodimers |